Radiotherapy for Benign Disease - Board Review Summary

PART I - BIG PICTURE, EVIDENCE, AND RISK

Management Paradigm + Dose Anchors

Clinical lane	Board-management frame	Dose scale
Painful inflammatory / degenerative disease	Consider only after diagnostic clarity and failed conservative therapy. Best fit is persistent pain with an inflammatory or insertional component, not severe mechanical destruction.	Usually 0.5 Gy x 6 = 3 Gy; acceptable range 0.5-1 Gy/fx to 3-6 Gy.
Fibroproliferative disease	Treat early active biology, not mature scar alone. Keloids are mainly post-excision RT; Dupuytren/Ledderhose are early-nodule diseases; Peyronie benefit is mainly pain relief in active plaques.	Condition-specific, commonly 10-30 Gy; Dupuytren/Ledderhose anchor 30 Gy split course.
Prophylaxis / prevention	HO prophylaxis is the clearest board indication. Gynecomastia prophylaxis is an option when tamoxifen is unsuitable or undesired.	HO 7-8 Gy x 1; gynecomastia commonly 9-15 Gy in 1-5 fx.
Selected benign tumors / tumor-like disease	Use RT selectively for symptomatic, progressive, unresectable, recurrent, or morbid disease after multidisciplinary review. Avoid reflex RT when observation or systemic therapy is favored.	Ranges from very low dose to conventional local-control doses, roughly 20-60 Gy depending disease.

Why This Topic Is Expanding Again

Benign RT is common in German-speaking practice and is slowly re-entering U.S. discussion, especially low-dose RT for painful inflammatory / degenerative conditions. The disciplined framing is: right condition, right biology, right stage, right dose, right counseling.

Mechanistic Buckets

Bucket	Examples	Radiobiologic goal	Typical dose scale
Inflammatory / degenerative	Osteoarthritis, plantar fasciitis, heel spur, epicondylitis, shoulder syndrome, trochanteric bursitis, Achillodynia	Immune modulation, reduced cytokine signaling, macrophage polarization, pain reduction	0.5-1 Gy/fx, total 3-6 Gy
Fibroproliferative	Keloids, Dupuytren disease, Ledderhose disease, Peyronie disease	Suppress fibroblast / myofibroblast proliferation and pathologic extracellular matrix production	Usually 10-30 Gy
Metaplastic / prophylactic	Heterotopic ossification, antiandrogen-associated gynecomastia	Prevent differentiation or hormonally driven proliferation	Single or short-course treatment
Rare benign tumors / disorders	Vertebral hemangioma, PVNS / TGCT, desmoid, Gorham-Stout disease, glomus tumor, AVM, lymphatic fistula	Local control, symptom control, or closure of pathologic leakage	Very disease-specific

Evidence Hierarchy

Evidence anchor	How to use it	Board-style takeaway
DEGRO / German S2e guideline	Useful for practical indications, target design, dose schedules, and equipment selection.	Best public framework for "how do I actually treat this?"
VA Evidence Synthesis Program review	Strict systematic review focused on comparative evidence and patient-centered outcomes.	Keeps the page honest: many benign RT indications have low or insufficient comparative certainty despite long clinical use.
Modern randomized signals	Most helpful for HO prevention, Ledderhose disease, plantar fasciitis, and selected OA questions.	Do not overgeneralize one positive condition to all benign RT indications.

Evidence synthesis: HO prevention is the cleanest board-tested indication. Plantar fasciitis and Ledderhose have meaningful randomized data, while OA data include large favorable retrospective cohorts, mixed sham-controlled results, and newer positive randomized knee OA signals in selected early-stage patients. Many other indications require careful shared decision-making.

Equipment and Depth Principles

Equipment	Typical use	Practical note
Superficial / orthovoltage X-ray	Skin, hand/foot, superficial tendons, Dupuytren / Ledderhose, keloids, pterygium in specialized practice	Useful when target depth is shallow and skin dose is intentional.
Electrons	Keloids, breast bud / gynecomastia, superficial fibromatoses, Peyronie plaques	Use bolus when skin, scar, or plaque coverage matters.
6-10 MV photons	Hip, shoulder, spine, larger joints, HO, orbit, PVNS, desmoid, glomus, AVM	Often requires 3D planning and OAR-conscious beam arrangement.
Brachytherapy / beta applicators	Pterygium, coronary in-stent restenosis, selected superficial lesions	Specialized workflows; not a general benign RT workhorse.

Risk Counseling

The second-malignancy risk is small but not zero and depends on age, sex, dose, field size, treated site, and organ proximity. Benign RT should be used cautiously in younger patients, near breast/thyroid/gonads/lens, or when conservative alternatives are equally effective. For low-dose joint RT in older adults, modeled risks are very low, but consent should still explicitly cover delayed response, no benefit, skin changes, and rare late effects.

PART II - LOW-DOSE RT FOR INFLAMMATORY / DEGENERATIVE DISEASE

Low-Dose Anti-Inflammatory Biology

LDRT works through immune modulation, not cancer-style cytoreduction. Mechanisms include reduced endothelial adhesion molecules, increased TGF-beta and IL-10, reduced IL-1beta / TNF-alpha / NF-kB signaling, decreased ROS and nitric oxide production, inflammatory-cell apoptosis, and macrophage polarization toward less inflammatory phenotypes. The most biologically active single-fraction range is often described around 0.3-0.7 Gy.

General Candidate Selection

Better candidate	Poor candidate
Age usually >40; symptoms persistent despite appropriate conservative therapy; pain has inflammatory or insertional features; imaging and exam fit; patient wants to avoid or delay invasive therapy; baseline pain/function score is documented.	Very young patient; uncertain diagnosis; active infection, malignancy, fracture, or severe mechanical instability; bone-on-bone end-stage joint disease; correctable surgical problem; field near high-risk organs without a compelling benefit.

General Dose Paradigm

Common practical regimen: 0.5 Gy x 6 to 3 Gy, delivered 2-3 times per week on nonconsecutive days. Many guideline-based schedules allow 0.5-1 Gy/fx to total 3-6 Gy, with a second series after about 6-12 weeks if response is inadequate or pain recurs. In modern practice, 0.5 Gy/fx is often favored when efficacy appears comparable.

Osteoarthritis

Site	Dose	Selection / technique	Evidence nuance
Knee OA	0.5-1 Gy x 6 = 3-6 Gy	Best fit is mild-to-moderate OA with inflammatory pain; include joint/capsule and symptomatic periarticular region; shield gonads when relevant.	Large retrospective cohorts are favorable; sham-controlled data are mixed; newer selected early-stage randomized data support pain/function benefit.
Hip OA	0.5-1 Gy x 6 = 3-6 Gy	Use photons with careful pelvic OAR and gonadal sparing; exclude severe mechanical destruction.	Less randomized evidence than knee; response more plausible in non-end-stage disease.
Hand / small-joint OA	0.5-1 Gy x 6 = 3-6 Gy	Shield fingernails when possible; treat involved joints or whole hand if multi-joint pattern supports it.	Response can be delayed; repeat series can help; field size and active symptomatic biology matter.
Ankle / foot OA	0.5-1 Gy x 6 = 3-6 Gy	Apply same LDRT principles with diagnosis-specific target design.	Use after conservative options and diagnostic clarity.

OA pitfall: do not treat a purely mechanical problem and expect an anti-inflammatory dose to rebuild cartilage. Severe varus/valgus deformity, bone-on-bone disease, instability, fracture, or surgical pathology should redirect management.

Plantar Heel Pain / Plantar Fasciitis / Heel Spur

Plantar fasciitis / heel spur is one of the better-supported LDRT indications. A practical board answer is: persistent symptoms, failed conservative therapy, usually age >40, exact pain localization, and 0.5 Gy x 6 with delayed response assessment.

Feature	Practical point
Indication	Painful plantar fasciitis / heel spur with symptoms generally >3 months and failure of conservative therapy.
Age	Avoid as a rule under 40; ages 30-40 only if conservative options are exhausted and benefit is compelling.
Dose	0.5 Gy x 6 = 3 Gy is the preferred anchor; 3-6 Gy total is an accepted range.
Technique	Orthovoltage direct plantar field or opposed low-energy photon fields; localize exact pain site; bolus heel edges if needed.
Response	Assess after several weeks; second course can be considered for persistent or recurrent pain.

Epicondylitis, Shoulder Syndrome, Trochanteric Bursitis

Condition	Dose	Technique / target	Board nuance
Medial / lateral epicondylitis	0.5 Gy x 6 = 3 Gy	Treat medial or lateral epicondyle and adjacent tendon/bony insertion; not the whole elbow capsule.	Second series can be considered after about 10-12 weeks.
Painful shoulder syndrome	0.5-1 Gy x 6 = 3-6 Gy	Include symptomatic bursa/tendon region; avoid lung and breast; smaller field for isolated supraspinatus/subdeltoid disease.	Consider only after conservative therapy failure; response is delayed.
Trochanteric bursitis / GTPS	0.5-1 Gy x 6 = 3-6 Gy	Include superficial/deep gluteal bursae and gluteofemoral bursa when clinically involved; MRI can help; maximize gonadal sparing.	Evidence is limited, so selection and consent matter.
Achillodynia / dorsal heel pain	0.5-1 Gy x 6 = 3-6 Gy	Treat painful Achilles tendon region and calcaneal tuberosity.	Use same LDRT logic as heel pain; exclude rupture or infection.

PART III - FIBROPROLIFERATIVE DISEASE

Keloids / Hypertrophic Scars

Keloid RT is mainly post-excision recurrence prevention. Primary RT for hypertrophic scars is not recommended, and monotherapy for unresected keloid is exceptional. Timing and BED matter: start the same day or within 24 hours when feasible; 24-72 hours is a common practical window.

Element	Practical point
Common modern dose	18 Gy / 3 fx for earlobe; 21 Gy / 3 fx for higher-risk sites such as chest, shoulder, trunk, and recurrent lesions.
Conservative lower-dose schedules	12-15 Gy in 3-5 fx can be used in selected lower-risk settings, but may be less durable for high-risk anatomy.
Field	Scar plus about 1.5-2 cm, edited anatomically.
Technique	Electrons with bolus, superficial/orthovoltage, or brachytherapy depending on site and equipment.
Toxicity	Erythema, desquamation, pigment change, telangiectasia; protect breast, thyroid, gonads, and lens when relevant.
Unresected keloid	Definitive RT such as 37.5 Gy / 5 fx has been described, but is not the standard first-choice pathway.

Dupuytren Disease

Feature	Practical point
Best stage	Early active disease with nodules/cords and no or minimal contracture.
Useful threshold	Best for Tubiana N or N/I; diminishing value once fixed contracture is >30 degrees. A positive tabletop test usually means procedural management is more relevant.
Preferred dose	3 Gy x 5, repeat after 8-12 weeks, total 30 Gy.
Alternative	3 Gy x 7 = 21 Gy every other day.
Technique	Mark nodules/cords on skin; photo-document; treat with 1-2 cm margin; shield uninvolved hand, nail beds, thenar/hypothenar tissue, and carpal tunnel when possible.

Board pearl: Dupuytren RT is not for fixed mature contracture. It is for active proliferative disease where fibroblasts/myofibroblasts are still a radiobiologic target.

Ledderhose Disease

Ledderhose disease is plantar fibromatosis and conceptually parallels Dupuytren disease. RT is considered for progressive symptomatic nodules or recurrence after surgery, with the same typical schedule: 3 Gy x 5, repeat after 8-12 weeks, total 30 Gy. Field design must balance nodule/cord coverage with protection of uninvolved plantar tissues.

LedRad is a high-yield update: randomized sham-controlled data showed that RT for symptomatic Ledderhose disease improved pain, quality of life, and barefoot walking ability without a clear toxicity penalty. This makes Ledderhose stronger than many other benign RT indications from an evidence standpoint.

Peyronie Disease / Induratio Penis Plastica

Feature	Practical point
Best candidate	Early painful inflammatory plaques, especially soft plaques; less useful for chronic calcified/fibrotic disease.
Dose	2-3 Gy/fx to total 10-20 Gy; broader historical ranges exist.
Technique	Orthovoltage, low-energy photons, or electrons; homogeneous corpus coverage; spare glans, pubic region, and scrotum.
Outcome	Pain relief is more predictable than curvature improvement.
Caveat	No randomized RT trials; spontaneous improvement can confound interpretation.

PART IV - HETEROTOPIC OSSIFICATION AND OTHER PROPHYLACTIC RT

Heterotopic Ossification

HO prophylaxis is one of the clearest benign RT indications. RT prevents new heterotopic bone formation; it does not dissolve mature established HO. The classic use case is high-risk hip surgery or HO excision.

Brooker Classification

Grade	Description
I	Islands of bone within soft tissue.
II	Bone spurs with at least 1 cm between opposing bone surfaces.
III	Bone spurs with less than 1 cm between opposing bone surfaces.
IV	Apparent ankylosis.

Dose, Timing, Technique

Element	Practical point
Dose	7-8 Gy x 1; high-risk cases may use 3.5 Gy x 5.
Timing	Preop within about 4 hours or postop within 72 hours; many workflows use postop within 24-72h.
Target	High-risk periarticular soft tissues; for hip include typical HO locations around greater/lesser trochanter, acetabulum, ilium, and ischium region.
Technique	Usually AP/PA photons; block pelvic OARs; scrotal shielding and fertility counseling when relevant.
Comparator	NSAIDs are also effective but can have GI, renal, bleeding, and fracture-healing concerns; RT is often favored when NSAIDs are unsuitable.

Gynecomastia Prophylaxis

Setting	Dose / approach	Key nuance
Antiandrogen-associated gynecomastia prevention	9-15 Gy in 3-5 fx or 10-15 Gy x 1; some practices use 4 Gy x 4.	Primarily for nonsteroidal antiandrogen exposure in prostate cancer.
Established symptomatic gynecomastia	Higher doses up to 30-40 Gy have been described.	Evidence weaker; consider hormonal, medication, or surgical alternatives.
Comparator	Tamoxifen often outperforms prophylactic RT in randomized data.	RT remains an option when medication is unsuitable or undesired.
Planning	Electrons, orthovoltage, or tangential photons.	Quantify heart/lung dose when anatomy or cardiac risk makes it relevant.

PART V - ORBIT, LYMPHATICS, AND RARE BENIGN TUMORS

Thyroid Eye Disease / Graves Orbitopathy

Feature	Practical point
Indication	Active inflammatory orbitopathy with ocular muscle dysfunction, diplopia, or steroid-responsive inflammatory symptoms.
Dose	Classic regimen 20 Gy / 10 fx; selected early inflammatory cases may use lower total doses such as 2.4-16 Gy.
Technique	Lateral opposed photon fields; cover posterior orbit / orbital apex and spare lenses.
Systemic context	Steroids remain common in active disease; teprotumumab is an approved systemic option for thyroid eye disease and has changed the non-RT landscape.
Clinical pearl	Patient should be euthyroid; RT is less useful in inactive fibrotic disease or fixed proptosis without active inflammation.

Orbital Pseudotumor / Idiopathic Orbital Inflammation

This is a diagnosis of exclusion. Steroids are usually first-line, but RT around 20 Gy / 10 fx can be useful for persistent, recurrent, or steroid-refractory disease. Keep lymphoma in the differential when the course is atypical.

Lymphatic Fistula / Lymphorrhea

Persistent lymphatic fistulas can respond to very low-dose RT after conservative or surgical approaches fail. Practical single doses such as 0.3-0.5 Gy may work well, often with total dose only 1-3 Gy, though broader ranges up to 15 Gy have been described. Target the fistula tract/reservoir plus margin, track drainage volume daily, and stop once secretion has ceased.

Rare Benign Tumor / Tumor-Like Conditions

Condition	When RT matters	Dose / technique	Board takeaway
Symptomatic vertebral hemangioma	Pain or neurologic symptoms without urgent decompression need; postop after incomplete decompression.	Conventional RT, usually at least 34-36 Gy.	Asymptomatic lesions do not need treatment.
PVNS / TGCT	Diffuse large-joint disease, incomplete resection, or high recurrence risk.	D-PVNS 36-40 Gy; localized/PVTS 20-36 Gy.	Goal remains maximal safe synovectomy; RT is adjuvant/selective.
Desmoid / aggressive fibromatosis	Progressive, unresectable, morbid location, R1/R2 or recurrent disease after multidisciplinary review.	Microscopic disease often 50 Gy; gross/recurrent disease roughly 55-60 Gy.	Modern management often starts with observation/systemic options, including nirogacestat for progressing tumors needing systemic therapy.
Gorham-Stout disease	Progressive osteolysis or symptomatic local progression.	36-45 Gy conventional RT with CT-based planning.	Rare; RT can stabilize local disease in selected progressive cases.
Pterygium	Adjuvant ocular surface treatment after excision in selected ophthalmic practice.	Beta applicator / brachytherapy approaches, often fractionated over early postop visits.	Specialized; know concept, not a routine general rad onc workflow.

PART VI - OTHER BOARD QUICK HITS

Selected Less-Common Indications

Condition	RT role	Dose / planning anchor	Board trap
Hidradenitis suppurativa	Historical or highly selected refractory Hurley stage II-III disease after maximal medical/surgical options.	Example 7.5 Gy / 5 fx; broader 4-15 Gy over 1-10 fx described.	Not a mainstream modern indication; do not treat active infection without appropriate management.
Brain AVM	SRS for small/moderate AVM where surgery/embolization is high risk or incomplete.	Margin dose often 16-30 Gy to the nidus depending size/location.	Obliteration takes about 2 years; hemorrhage risk persists during latency.
Glomus tumor / paraganglioma	Definitive RT or postop RT for skull-base lesions when surgery is morbid/incomplete.	Fractionated 45-50 Gy; SRS often 14-16 Gy.	Goal is durable control with cranial-nerve preservation, not rapid shrinkage.
Juvenile nasopharyngeal angiofibroma	RT for unresectable, recurrent, or intracranial-extending disease after expert ENT/neurosurgical review.	Often 30-36 Gy, up to about 50 Gy for difficult disease.	Do not biopsy a classic vascular JNA presentation casually; bleeding risk is high.
Langerhans cell histiocytosis	Selected painful bone lesions or fracture-risk lesions when local therapy is needed.	Low dose, often 6-8 Gy.	Systemic and pediatric context matters; avoid overtreatment.
Coronary in-stent restenosis	Specialized intravascular brachytherapy after drug-eluting stent failure in selected centers.	Often 15-20 Gy x 1 at specified vessel depth.	This is a cardiology-brachytherapy workflow, not external-beam chest RT.
Splenomegaly	Palliation of painful massive spleen or cytopenia-related symptoms in selected hematologic disease.	5 Gy / 5 or 10 Gy / 10 with blood-count monitoring.	Monitor cytopenias closely; response can be brisk.
Refractory plantar warts	Rare historical indication after dermatologic options fail.	Single-fraction approaches such as 10 Gy x 1 have been described.	Rarely used; consent and alternatives are central.
Ventricular tachycardia	Emerging noninvasive cardiac radioablation for refractory VT in trial/specialized settings.	Often 20-25 Gy x 1 to arrhythmogenic scar.	Investigational/specialized; requires electrophysiology-driven target definition.

PART VII - PRACTICAL WORKFLOW

Benign RT Workup Checklist

Confirm diagnosis with the appropriate specialist when possible: orthopedics, rheumatology, dermatology, plastic surgery, hand surgery, ophthalmology, urology, thyroid clinic, cardiology, or ENT.
Document failed or unsuitable conservative therapies.
Record baseline pain, function, photos, measurements, and disease stage using a reproducible score when available.
Use the smallest field that reliably covers the symptomatic biology, not the biggest anatomic region you can justify.
Shield gonads, lens, breast, thyroid, nail beds, and other sensitive structures whenever feasible.
Consent explicitly for small second-malignancy risk, skin changes, delayed response, possibility of no benefit, and alternative non-RT options.

Response Assessment

Benign RT response is often delayed. Assess inflammatory/pain indications at about 6-8 weeks and again later. For fibromatoses, document nodules/cords and function over months to years. For HO, evaluate radiographs and range of motion. For lymphatic fistulas, drainage volume is the endpoint.

CROSS-CUTTING HIGH-YIELD POINTS

Benign RT is not one thing: inflammatory LDRT, fibroproliferative RT, prophylactic RT, and rare benign tumor RT use different biology and dose scales.
LDRT mechanism: anti-inflammatory immune modulation, especially around 0.3-0.7 Gy/fx.
Common LDRT regimen: 0.5 Gy x 6 = 3 Gy, 2-3 fractions per week.
Typical LDRT range: 0.5-1 Gy/fx to 3-6 Gy for many painful degenerative/inflammatory indications.
Evidence caveat: many benign RT indications have low or insufficient comparative certainty despite long clinical use.
Plantar fasciitis / heel spur: one of the stronger LDRT indications; symptoms should generally persist >3 months and age is usually >40.
OA patient selection: avoid severe mechanical/bone-on-bone disease; select mild-to-moderate inflammatory pain phenotypes.
Epicondylitis: 0.5 Gy x 6; treat epicondyle/tendon insertion, not the whole elbow.
Keloids: best as immediate post-excision RT, ideally same day or within 24 hours.
Keloid dose: memorize 18 Gy / 3 for earlobe and 21 Gy / 3 for higher-risk sites.
Dupuytren / Ledderhose: treat early active proliferative disease, not fixed mature contracture.
Dupuytren / Ledderhose dose: 3 Gy x 5, repeat after 8-12 weeks, total 30 Gy.
Ledderhose: randomized sham-controlled data support pain and QOL benefit.
Peyronie: consider only active painful plaques; curvature improvement is less reliable than pain relief.
HO prophylaxis: 7-8 Gy x 1 within 4h preop or 72h postop; RT prevents new bone, not mature HO.
Thyroid eye disease: active disease with ocular muscle dysfunction; classic 20 Gy / 10 but lower-dose schedules and systemic alternatives exist.
Gynecomastia prophylaxis: 9-15 Gy in 1-5 fx; tamoxifen often more effective.
Desmoid: observation/systemic therapy is often first; RT is selected for progressive, morbid, unresectable, or recurrent cases.
AVM SRS: target the nidus; hemorrhage risk persists during the latency to obliteration.
JNA: avoid casual biopsy because of bleeding risk.
Second malignancy counseling: small but not zero; age, field, dose, organ proximity, and alternatives matter.

CONSOLIDATED DOSE TABLE

Condition	Dose / schedule	Comment
OA / inflammatory LDRT	0.5 Gy x 6 = 3 Gy	Common modern practical regimen.
OA / shoulder / bursitis guideline range	0.5-1 Gy/fx to 3-6 Gy	2-3 fractions weekly; repeat course possible.
Plantar fasciitis / heel spur	0.5 Gy x 6 = 3 Gy	Persistent symptoms after conservative therapy.
Epicondylitis	0.5 Gy x 6 = 3 Gy	Second series after 10-12 weeks if needed.
Keloid, earlobe	18 Gy / 3 fx	Post-excision, ideally same day or within 24h.
Keloid, higher-risk site	21 Gy / 3 fx	Chest, shoulder, trunk, recurrent lesions.
Keloid conservative schedule	12-15 Gy / 3-5 fx	Selected lower-risk settings.
Dupuytren disease	3 Gy x 5, repeat after 8-12 wk	Total 30 Gy; active early disease.
Ledderhose disease	3 Gy x 5, repeat after 8-12 wk	Total 30 Gy; symptomatic progressive nodules.
Peyronie disease	2-3 Gy/fx to 10-20 Gy	Active painful plaques; spare glans/scrotum.
Heterotopic ossification	7-8 Gy x 1	Preop <4h or postop <72h.
HO high-risk fractionated option	3.5 Gy x 5	Selected high-risk settings.
Gynecomastia prophylaxis	9-15 Gy / 1-5 fx	Antiandrogen-associated; tamoxifen often more effective.
Thyroid eye disease	20 Gy / 10 fx	Classic active/moderate disease approach; lower-dose regimens exist.
Orbital pseudotumor	20 Gy / 10 fx	Steroid-refractory or recurrent disease.
Lymphatic fistula	0.3-0.5 Gy/fx, often 1-3 Gy total	Stop when drainage ceases.
Vertebral hemangioma	34-36 Gy	Symptomatic disease without urgent decompression need.
PVNS / TGCT diffuse	36-40 Gy	Adjuvant/selective after incomplete resection or high recurrence risk.
Desmoid microscopic disease	50 Gy	Selected progressive/morbid cases after multidisciplinary review.
Desmoid gross/recurrent disease	55-60 Gy	Use cautiously in young patients and large fields.
Gorham-Stout disease	36-45 Gy	Progressive osteolysis.
Hidradenitis suppurativa	7.5 Gy / 5 fx	Highly selected refractory disease.
Brain AVM SRS	16-30 Gy x 1	Target nidus; latency to obliteration.
Glomus / paraganglioma	45-50 Gy or 14-16 Gy SRS	Durable control / cranial-nerve preservation.
Juvenile nasopharyngeal angiofibroma	30-36 Gy, up to 50 Gy	Unresectable/recurrent/intracranial disease.
Langerhans cell histiocytosis bone lesion	6-8 Gy	Selected painful or fracture-risk lesions.
Coronary in-stent restenosis	15-20 Gy x 1	Specialized intravascular brachytherapy.
Splenomegaly	5 Gy / 5 or 10 Gy / 10	Monitor blood counts.
Refractory plantar warts	10 Gy x 1	Rare historical use.
Refractory ventricular tachycardia	20-25 Gy x 1	Emerging trial/specialized cardiac radioablation.

KEY EVIDENCE ANCHORS

Anchor	Scope	One-line takeaway
DEGRO / German S2e guideline	Benign RT indications and dose schedules	Practical public framework for dose, technique, and recommendation levels.
VA Evidence Synthesis Program review	Systematic evidence review for prioritized benign conditions	Many indications have low or insufficient comparative certainty despite long clinical use.
Large German LDRT cohorts	Low-dose RT for painful degenerative disease	Retrospective experience supports symptom improvement with minimal toxicity in selected adults.
Plantar fasciitis randomized trials	Heel spur / plantar fasciitis	Support dose de-escalation to 0.5 Gy x 6 in many patients.
LedRad	Ledderhose disease	Randomized sham-controlled trial showing pain and quality-of-life benefit.
Dupuytren long-term series	Dupuytren disease	RT reduces progression/surgery in early active disease; out-of-field progression matters.
HO randomized trials	Heterotopic ossification	7-8 Gy x 1 is effective; preop and postop timing can both work.
Thyroid eye disease randomized data	Graves orbitopathy	Orbital RT is most useful in active inflammatory disease with muscle dysfunction, often with steroids.
Rare tumor series	PVNS, vertebral hemangioma, desmoid, glomus, JNA	Conventional RT can provide durable local/symptom control in selected symptomatic or recurrent disease.